5-Amino-1MQ vs Eloralintide
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
5-Amino-1MQGLP-1 / Weight Loss Agonists
Eloralintide- Summary
- 5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Half-Life
- Estimated 4–8 hours
- ~7 days (estimated, long-acting design)
- Admin Route
- Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 50–100 mg
- Under investigation in Phase 1/2 trials
- Frequency
- Once to twice daily
- Once weekly
- Key Benefits
- Raises intracellular NAD+ levels
- Directly targets adipose tissue for fat reduction
- Reduces fat cell size and differentiation
- Increases basal metabolic rate
- SIRT1 activation for metabolic regulation
- No stimulant cardiovascular side effects
- Synergistic with intermittent fasting and caloric restriction
- May have anti-aging metabolic benefits
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Side Effects
- Generally well-tolerated in available studies
- Mild GI discomfort (rare)
- Limited long-term human data
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Stacks With
- —
- —